Fresh Tracks Therapeutics Inc (FRTX) Return on Equity ROE from the fourth quarter 2023 to fourth quarter 2022 and annually, average high and low, overall ranking from Dec 31 2023 to Dec 31 2022 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Fresh Tracks Therapeutics Inc   (FRTX)

Fresh Tracks Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Fresh Tracks Therapeutics Inc in the fourth quarter 2023?
Fresh Tracks Therapeutics Inc recorded a cumulative net loss of $-6 million during 12 months ending in the fourth quarter 2023, resulting in a negative return on equity (ROE) of -58.8%.

Within the Biotechnology & Pharmaceuticals industry 64 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2023 from 3486 to 3607.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2023)
IV. Quarter		 (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter
Y / Y Equity Change 38.03 % -2.44 % -48.89 % -38.52 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -6 -9 -17 -16 -21
Return On Equity (TTM) -58.8 % -102 % -188.61 % -145.43 % -168.47 %
FRTX's Total Ranking # 3607 # 3486 # 3836 # 3695 # 4010
Equity (TTM) in Millions 10 11 8 10 7
Seq. Equity Change -9.31 % 37 % -18.99 % 37.14 % -35.9 %
Seq. Net Income Change - - - - -

Back to FRTX Management Effectiveness >> FRTX's 5 Years Annual ROE >> Compare FRTX ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 65
Sector # 485
Overall # 3607

Return On Equity Statistics
High Average Low
-11.97 %
-64.22 %
-191.55 %
(Dec 31 2019)   (Mar 31 2022)





FRTX Annual Return On Equity (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019
Total Equity in Millions 10 7 25 27 8
Y / Y Equity Change 38.03 % -71.12 % -8.21 % 258.27 % -84.47 %
Net Income in Millions -6 -21 -39 -21 -3
Y / Y Net Income Change - - - - -
Return On Equity -57.34 % -293.33 % -158.49 % -77.07 % -43.95 %

Back to FRTX Management Effectiveness >> FRTX's 5 Years Annual ROE >> Compare FRTX ROE to its Competitors




More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
FRTX's' Return on Equity at Yahoo Finance
FRTX's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for FRTX's Competitors
Subscribers only: Roe for Fresh Tracks Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for FRTX's Customers




Companies with similar Return On Equity at Dec 31 2023, within Healthcare Sector ROE

Date modified: 2026-06-22T14:32:37+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.